前列腺癌 41
- Enrollment goal met in trial of individualized ADT/RT for high-risk prostate cancer
- 拜登的前列腺癌诊断凸显了筛查和意识的重要性
- 基因组检测可以预测前列腺癌对化疗的耐药性
- 177 Lu-rhPSMA-10.1注射液在mCRPC中显示出阳性辐射剂量测定结果
- Botulinum toxin reduces PSMA therapy-related salivary gland toxicity
- FDA扩大Illuccix标签，纳入在紫杉醇前环境中进行RLT的患者选择
- CHMP建议欧盟批准达罗鲁米特加ADT用于mHSPC
- CHMP recommends EU approval of darolutamide plus ADT in mHSPC
- Data link incontinence severity to post-radical prostatectomy care
- 现实世界研究比较了mCSPC中ARPI之间的总生存率
- Real-world studies compare overall survival between ARPIs in mCSPC
- Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
- 在mCRPC中启动伊非那他玛德鲁克替康与化疗的3期试验
- 评估ArteraAI对前列腺癌临床决策影响的研究
- Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
- Jim Hu，医学博士谈根治性前列腺切除术中GG 1前列腺癌的升级
- Expert discusses differentiating prostate cancer from age-related issues
- FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
- FDA不批准他拉唑帕利加恩杂鲁胺治疗非HRR基因突变的mCRPC
- Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
- 不同mHSPC人群中剩余未满足的需求
- Improving diversity in future clinical trials for mHSPC
- Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
- 64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence
- AI-based tool aims to optimize MRI use in prostate cancer diagnosis
- PSMA-PET成像产品Gozellix在美国市场推出
- Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
- AI预测技术革新前列腺癌治疗
- 机器人辅助前列腺癌根治术
- 青少年饮酒与生命后期的前列腺癌相关吗？
- 新辅助激素治疗高危前列腺癌的研究
- NCCN前列腺癌指南
- 前列腺癌Gleason 评分
- 前列腺癌
- 研究发现前列腺癌可能起源于前列腺基质细胞
- 超过75%的低危前列腺癌存在过度治疗
- 前列腺癌体积大小和患者的BMI有关
- Provenge成美国第一个癌症治疗疫苗
- 研究认为度他雄胺可用来预防前列腺癌
- 男性30岁前秃顶意味着前列腺癌风险低
- Avastin治疗前列腺癌试验失败